Genetic factors can account for up to 95% of drug-response variability and susceptibility.3 In other words, how a drug will—or won't—work for a particular individual. Our RightMed® test brings pharmacogenomics to everyone, identifying how a patient's DNA and current medications may affect their response to drugs. OneOme: making prescriptions personal.
RIGOROUS: Characterized by scientific and clinical data4,5
COMPREHENSIVE: Covers hundreds of medications for many medical conditions
INTERACTIVE: Includes the RightMed Advisor, an online clinical decision support tool for providers, which offers custom report options
CREDIBLE: Co-developed and exclusively licensed with Mayo Clinic
ACCESSIBLE: Provided at a low-cost with multiple billing options available
SUPPORTIVE: Offers complementary consultations with clinical pharamcists, in addition to customer support
Cost-effective, comprehensive, personalized pharmacogenomic analysis — integrated into patients' everyday clinical care.
OneOme helps healthcare providers choose the optimal drug therapy the first time, thanks to targeted and evidence-based inputs using each patient's DNA and current prescriptions.
The physician-ordered OneOme RightMed comprehensive test identifies which prescription drugs are—or aren’t—likely to work based on your genetic makeup and current prescription interactions. OneOme generates a clear, actionable report to help your physicians to personalize your prescriptions.
MINNEAPOLIS (MAY 22, 2018) — OneOme, co-developed by Mayo Clinic, today announced several significant enhancements to its product offering, including the addition of four new genes (HLA-A, HLA-B, CYP4F2, and CYP2C Cluster) and nine new medications ...
OneOme will be attending the Individualizing Medicine Conference 2018 September 12 - 13 in Rochester, MN.
MINNEAPOLIS (February 20, 2018) – OneOme, a healthcare technology company whose genetic test helps predict how a person will respond to hundreds of medications and enables healthcare providers to prescribe more effective medications, today announced that it is included in Fast Company’s annual ranking of the 50 Most Innovative Companies for 2018.
In this webinar, we will:
MINNEAPOLIS (January 10, 2018) – Precision medicine company OneOme is partnering with PWNHealth to increase patient access to the RightMed® comprehensive test without compromising patient safety.
Until now, patients interested in the RightMed test could only get it by talking to their doctor. Th ...
OneOme will be attending the Advanced Practice Providers Oncology Summit September 14-15 in Denver, CO.
“Before OneOme, only those with deep financial resources or the critically ill could access the power of pharmacogenomics. Today, patients at Ridgeview can receive personalized prescription insights that previously were inaccessible to them. Not only will our patients see better health outcomes – they are also avoiding life-threatening adverse drug reactions, which are the fourth leading cause of death.”
- Bob Stevens, President and CEO of Ridgeview Medical Center